Figure 5
Ex vivo binding activity of anti-CD20 IgG1 rituximab variants to FcγRIIIa on NK cells. Heparinized peripheral blood from donor 4, or blood depleted of auto-plasma by washing and reconstitution with stain buffer, was incubated with serial dilutions of anti-CD20 IgG1s. Anti-CD20 IgG1 rituximab variants bound to FcγRIIIa on CD3-CD56+ NK cells after incubation on ice for 30 min were detected by anti-rituximab-FITC.